Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Economic evaluation of multiple sclerosis in the UK, Germany and France.
Murphy N, Confavreux C, Haas J, König N, Roullet E, Sailer M, Swash M, Young C, Mérot JL; Cost of Multiple Sclerosis Study Group. Murphy N, et al. Among authors: haas j. Pharmacoeconomics. 1998 May;13(5 Pt 2):607-22. doi: 10.2165/00019053-199813050-00013. Pharmacoeconomics. 1998. PMID: 17165327
Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker … See abstract for full author list ➔ Rieckmann P, et al. Among authors: haas j. J Neurol. 2004 Nov;251(11):1329-39. doi: 10.1007/s00415-004-0537-6. J Neurol. 2004. PMID: 15592728 Review.
Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S, Hoshi MM, Pul R, Wahl M, Schwab M, Haas J, Ellrichmann G, Krumbholz M, Tackenberg B, Saum KU, Buck F, Leemhuis J, Kretschmann A, Aktas O. Rauer S, et al. Among authors: haas j. Clin Neurol Neurosurg. 2020 Oct;197:106142. doi: 10.1016/j.clineuro.2020.106142. Epub 2020 Aug 12. Clin Neurol Neurosurg. 2020. PMID: 32920498 Free article.
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
Ziemssen T, Lang M, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Lang S, Winkelmann VE, Ettle B, Schulze-Topphoff U; PANGAEA study group. Ziemssen T, et al. Among authors: haas j. J Neurol. 2022 Jun;269(6):3276-3285. doi: 10.1007/s00415-021-10931-w. Epub 2022 Jan 4. J Neurol. 2022. PMID: 34982201 Free PMC article.
2,390 results